Status:
COMPLETED
Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction
Lead Sponsor:
Fudan University
Conditions:
Acute Myocardial Infarction
Percutaneous Coronary Intervention
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy of three different vasodilators including diltiazem, verapamil and nitroglycerin for reversal of no-reflow/slow-flow during direct percutaneous co...
Detailed Description
No-reflow/slow-flow is a frequent observation during direct PCI for AMI and associated with a poor clinical outcome. The present pharmacological management involves the use of different vasodilators i...
Eligibility Criteria
Inclusion
- Clinical diagnosis of acute myocardial infarction
- Vessel TIMI flow \< grade Ⅲ post-PCI
Exclusion
- Heart failure of New York Heart Association (NYHA) class Ⅲ to class Ⅳ
- Sick sinus syndrome
- Atrioventricular block (grade Ⅱ and above)
- SBP ≤ 90mmHg or cardiogenic shock
- Heart Rate ≤60 bpm
- Pregnancy
- Renal or hepatic failure
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00712894
Start Date
December 1 2006
End Date
August 1 2009
Last Update
September 24 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China, 200032